Search research articles
Contact Us
Filters
Showing results (61-70 of 138) with videos related to
Page
of 14
Sort By:
Blood Advances
|
March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
Joachim Yahalom, Amy J Xu, Ariela Noy, et al.
Haematologica
|
August 24, 2014
A new prognostic score for AIDS-related lymphomas in the rituximab-era
Stefan K Barta, Xiaonan Xue, Dan Wang, et al.
British Journal of Haematology
|
April 11, 2016
Central nervous system involvement in AIDS-related lymphomas
Stefan K Barta, Jitesh Joshi, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
Alison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology
|
October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
Owen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Cancer
|
October 6, 2005
Developing a cancer-specific geriatric assessment: a feasibility study
Arti Hurria, Supriya Gupta, Marjorie Zauderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
Blood
|
February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy, Sven de Vos, Catherine Thieblemont, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 138) with videos related to
Sort By:
Page
of 14
Blood Advances
|
March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
Joachim Yahalom, Amy J Xu, Ariela Noy, et al.
Haematologica
|
August 24, 2014
A new prognostic score for AIDS-related lymphomas in the rituximab-era
Stefan K Barta, Xiaonan Xue, Dan Wang, et al.
British Journal of Haematology
|
April 11, 2016
Central nervous system involvement in AIDS-related lymphomas
Stefan K Barta, Jitesh Joshi, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
Alison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology
|
October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
Owen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Cancer
|
October 6, 2005
Developing a cancer-specific geriatric assessment: a feasibility study
Arti Hurria, Supriya Gupta, Marjorie Zauderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
John Gerecitano, Carol Portlock, Paul Hamlin, et al.
Blood
|
February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy, Sven de Vos, Catherine Thieblemont, et al.
Blood
|
December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Page
of 14